In Imamiyyah jurisprudence, the manufacturer of unsafe medicinal products should be held accountable, based on general rules such as waste and harm. EU law also provides for severe and effective sanctions as well as deterrents. Iranian law also needs to be upgraded, and the applicable safeguards in the laws should be amended and modified in order to strengthen its deterrence. In the EU, the supplier must provide information on unsafe medicines to reduce the risk of harm caused by unsafe drugs distribution, which is the obligation of the manufacturer based on the Rule of Tolerance in Imamiyah jurisprudence. In the European :union:, the manufacturer of pharmaceutical products should reduce the scope for misuse of its manufactured drugs. It also promotes consumer confidence in the health of pharmaceuticals by establishing institutions such as the possibility of extradition and exchange of goods, to increase consumer safety, and in the in the European :union:, there is also a special regulatory system for pharmaceutical manufacturers which is distinct from other regulatory systems that protect the consumer rights of other products are separate. Iran's law, in support of the consumer's rights to medicinal products, should be established by the principles and principles of common jurisprudence, by observing the institutions and recommendations of EU law and by observing their domestic laws.